Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06554158 · ClinicalTrials.gov registry record · NA
De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers
A NA study of Oropharynx Cancer, sponsored by Georgetown University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06554158: Recruiting NA study of Oropharynx Cancer, sponsored by Georgetown University.
NCT06554158 is a NA study of Oropharynx Cancer that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 30 participants, below the 131-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06554158, a NA study of Oropharynx Cancer, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether for intermediate-risk patients who have undergone Transoral Robotic Surgery for HPV/p16(+) oropharyngeal cancer and have minimal smoking history, whether these patients can be treated with a lower-than standard dose, with omission of the primary site in the oropharynx. The main questions it aims to answer are: Does radiotherapy site and dose-de-escalation lead to similar outcomes compared to historical data on tumor control in patients who are treated with standard radiation doses and treatment fields? Participants will: Undergo treatment with a lower than standard radiation dose (50Gy in 25 fractions, with either Intensity Modulated Radiation Therapy (IMRT) or proton beam therapy) and to a smaller than standard radiation field (to the neck only, excluding the original site of tumor in the oropharynx)
Primary Outcome
2 year progression free survival, as determined by standard of care physical examination and standard of care surveillance imaging.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (1)
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT06554158 shows while recruiting
NCT06554158 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 131-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Oropharynx Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT06554158 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06554158 about?
NCT06554158 is a clinical study titled "De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers". The goal of this clinical trial is to learn whether for intermediate-risk patients who have undergone Transoral Robotic Surgery for HPV/p16(+) oropharyngeal cancer and have minimal smoking history, whether these patients can be treated with a lower-than standard dose, with omission of the primary si...
What is the current status of trial NCT06554158?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-08-01. Estimated completion is 2028-12-31.
What conditions does trial NCT06554158 study?
This clinical trial studies the following conditions: Oropharynx Cancer.
What interventions are being tested in trial NCT06554158?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06554158?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06554158 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06554158's enrollment target sits among peer trials
30 18th of 26 higher than 7 of 26 other Oropharynx Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharynx Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
RECRUITING · NA
-
Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly
RECRUITING · NA
-
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx
RECRUITING · NA
-
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
ACTIVE NOT RECRUITING · NA
-
Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer
COMPLETED · NA
-
Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI